多纳非尼治疗进展性局部晚期或转移性放射性碘难治性分化型甲状腺癌:随机多中心II期试验结果
在中国12个中心纳入35例可测量病灶的RAIR-DTC患者,随机接受多纳非尼200mg或300mg每日两次口服24周。两臂24周ORR分别为12.5%和13.33%(p=1.000),300mg组中位PFS非显著延长(14.98 vs 9.44个月,p=0.351)。多纳非尼总体耐受良好,两方案疗效相似。
要点
- 多纳非尼200mg和300mg每日两次在RAIR-DTC中24周ORR相似(12.5% vs 13.33%)。
- 300mg组中位PFS非显著长于200mg组(14.98 vs 9.44个月,p=0.351)。
- 常见3级治疗相关不良事件为手足综合征和高血压,两臂合计发生率分别为11.43%和22.86%。
核心结论
- 多纳非尼总体耐受良好,两种剂量方案在局部晚期或转移性RAIR-DTC中ORR相似。
- 结果支持进一步研究多纳非尼作为RAIR-DTC可行治疗选择。
研究设计与样本
- 随机、开放标签、多中心II期试验,在中国12个中心纳入35例成人RAIR-DTC患者。
- 患者随机接受多纳非尼200mg(17例)或300mg(18例)口服每日两次,持续24周。
- 主要终点为ORR,次要终点包括PFS等,并评估生化(血清甲状腺球蛋白)和结构(总肿瘤直径)反应及安全性。
主要发现
- 200mg和300mg臂的ORR分别为12.5%和13.33%(p=1.000)。
- 300mg臂中位PFS非显著长于200mg臂(14.98个月 vs 9.44个月,p=0.351)。
- 300mg臂较200mg臂有更多肿瘤缩小趋势(平均ΔTTD率 -0.52 ± 0.71 vs -0.04 ± 1.55 mm/月,p=0.103)。
- 两臂大多数治疗相关不良事件为1-2级。
- 两臂最常见的3级治疗相关不良事件为手足综合征和高血压,200mg和300mg臂合计发生率分别为11.43%和22.86%。
关键数值与推荐
- 入组标准:成人RAIR-DTC,至少一个按RECIST 1.1可测量的靶病灶。
- 主要终点24周ORR:200mg臂12.5%,300mg臂13.33%(p=1.000)。
- 中位PFS:300mg臂14.98个月,200mg臂9.44个月(p=0.351)。
临床怎么用
- 多纳非尼200mg或300mg每日两次均可作为RAIR-DTC的潜在治疗选择,需关注手足综合征和高血压。
- 两种剂量疗效相似,剂量选择需结合安全性与耐受性个体化考虑。
局限性
- 样本量较小(共35例),II期探索性结果需III期研究验证。
- 两组ORR和PFS差异均未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: An unmet need for more effective and affordable kinase inhibitors remains in patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) in China, where only sorafenib is approved for this indication. This study evaluated the 24-week objective response rate (ORR) to donafenib-a new, domestic multikinase inhibitor-in the treatment of locally advanced or metastatic RAIR-DTC in patients with measurable lesions. Two dose regimens (300 mg twice daily vs. 200 mg twice daily) were used to determine its optimal dosage and safety for further phase III studies. Methods: This study was a randomized, open-label, multicenter phase II trial. Thirty-five adult RAIR-DTC patients with at least one measurable targeted lesion according to RECIST 1.1 were enrolled from 12 centers in China and randomized to receive either 200 mg (17 patients) or 300 mg (18 patients) of donafenib orally twice daily for 24 weeks. The primary endpoint was ORR, and the secondary endpoints included progression-free survival (PFS) among others. Additionally, biochemical (serum thyroglobulin) and structural (total tumor diameter [TTD]) responses were assessed, change (ΔTTD) rates were calculated, and safety was evaluated. Results: The ORRs for the 200- and 300-mg arms were 12.5% and 13.33% (p = 1.000), respectively. The 300-mg arm had a nonsignificant, longer median PFS than the 200-mg arm (14.98 months vs. 9.44 months) (p = 0.351). There was a trend toward more tumor shrinkage in the 300-mg arm compared with the 200-mg arm (average ΔTTD rate -0.52 ± 0.71 vs. -0.04 ± 1.55 mm/month, p = 0.103). Most treatment-related adverse events (AEs) in both arms were grades 1-2. The most common grade 3 treatment-related AEs in both arms were palmar-plantar erythrodysesthesia and hypertension; the sum occurrence rates of these two AEs in the 200-mg and 300-mg arms were 11.43% and 22.86%, respectively. Conclusions: Donafenib was generally well tolerated. Both donafenib regimens demonstrated similar efficacy in terms of the ORR in locally advanced or metastatic RAIR-DTC. The results warrant further studies on donafenib as a new, feasible treatment option for RAIR-DTC patients. Clinical Trials.gov IDs: NCT02870569; CTR20160220.
引用
- Lin YS, Yang H, Ding Y, et al. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial. Thyroid. 2020. PMID: 32907500. doi:10.1089/thy.2020.0235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。